Biotron Limited (ASX:BITO)

Market Cap	6.75M -53.2%
Revenue (ttm)	-868.00 +10.2%
Net Income	-1.94M
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	500,000
Average Volume	1,831,378
Open	0.0010
Previous Close	0.0010
Day's Range	0.0010 - 0.0010
52-Week Range	0.0010 - 0.0010
Beta	n/a
RSI	n/a
Earnings Date	May 27, 2026

About Biotron

Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company’s lead antiviral drug is BIT225 for the treatment of SARS-CoV-2, HIV-1, hepatitis C virus, hepatitis B virus (HBV), influenza, and dengue virus infections. The company was incorporated in 1999 and is based in Sydney, Australia.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 3
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: BITO

Financial Performance

In fiscal year 2025, Biotron's revenue was 1.81 million, an increase of 10.24% compared to the previous year's 1.65 million. Losses were -318,572, -90.73% less than in 2024.